[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"yellow-fever\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:yellow-fever":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,115,146,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":84,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":114},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537",false,"NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.",true,"ALL","2 Years","75 Years",{"count":21,"type":22},10000,"ESTIMATED","OBSERVATIONAL","RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83],"Dengue","Chikungunya","Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":105,"type":106},"2026-01-22","ACTUAL",{"date":108,"type":106},"2025-12-18",{"date":110,"type":22},"2027-09-30",{"name":112,"class":113},"Institut Pasteur du Cambodge","OTHER",1,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":16,"sex":17,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":126,"phases":127,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":114},"100505294","phase-1-immunogenicity-of-yellow-fever-vaccine-17d-in-adults-with-prior-17d-vaccination-100505294","NCT05859490","Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination","A Phase I\u002FII Study Of The Immunogenicity Of The Yellow Fever Vaccine 17D (YFVax®) In Adults With Prior 17D Vaccination","Inclusion Criteria:\n\n1. Aged ≥20 to \\\u003C50 years.\n2. Male or female.\n3. In good health at the time of screening as determined by medical history, physical examination, and clinical judgement of the investigator.\n4. Documented history of Yellow fever vaccination 8 or more years prior. Documentation must be on a primary (not copied) vaccination card or a fully completed electronic medical record entry including date of administration and lot number administered.\n5. Subjects who can comply with all trial procedures and are available for the duration of follow-up.\n\nExclusion Criteria:\n\n1. A clinically active infection or self-reported body temperature ≥38°C (100.4°F) within 3 days of scheduled date of vaccination (consider whether the finding is an exclusion criterion or criterion for delay of vaccination see Section 8.3).\n2. A known hypersensitivity or allergy to any of the trial vaccine components including eggs.\n3. Behavioral\u002Fcognitive impairment that, in the investigator's opinion, may interfere with the subject's ability to participate safely in the trial.\n4. Any history of neurologic disorder, seizure disorder or neuro-inflammatory disease.\n5. Any illness, or history of any illness that, in the investigator's opinion, could interfere with the trial or pose an additional risk to the subject during the trial period.\n6. Known or suspected impairment\u002Falteration of immune function, including:\n\n   1. Chronic use of oral steroids within 60 days prior to enrollment. Inhaled steroids are allowed.\n   2. Receipt of parenteral steroids within 60 days prior to screening visit.\n   3. Receipt of immunoglobulins and\u002For any blood products within the 3 months prior to enrollment or planned receipt during the trial.\n   4. Receipt of immunostimulants within 60 days prior to screening visit\n   5. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months of enrollment.\n   6. Known Human Immunodeficiency Virus (HIV) infection or HIV-related disease.\n   7. Hepatitis C virus infection.\n   8. Genetic immunodeficiency.\n7. History of splenic or thymic dysfunction.\n8. Any serious chronic or progressive disease as assessed by the investigator (eg, neoplasm, hematologic malignancies, insulin dependent diabetes; cardiac, renal, or hepatic disease).\n9. Body Mass Index (BMI) greater than or equal to 35 kg\u002Fm2.\n10. Concurrent participation in any clinical trial with another investigational product 30 days prior to or during the conduct of this trial.\n11. Vaccination within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment or plans to receive any vaccine within 28 days of trial vaccine administration (consider whether applicable as an exclusion criterion or criterion for delay of trial vaccine administration).\n12. Use of antipyretics and\u002For analgesic medications within 24 hours prior to vaccination. Trial entry should be delayed to allow for a full 24-hours to have passed since last use of antipyretics and\u002For analgesic medications (consider whether applicable as an exclusion criterion or criterion for delay of trial vaccine administration).\n13. Subjects with history of substance or alcohol abuse within the past 2 years.\n14. Subjects who are pregnant or breastfeeding.\n15. Subjects of childbearing potential who are sexually active with men and have not used \"acceptable contraceptive methods\" for at least 2 months prior to enrollment.\n\n    1. Of \"childbearing potential\" is defined as beyond onset of menarche and not: menopausal for 2 or more years, post bilateral tubal ligation at 1 year prior, post bilateral oophorectomy for at least 1 year or post hysterectomy.\n    2. \"Acceptable birth control methods\" include:\n\n    \u003C!-- -->\n\n    1. Hormonal contraceptives (such as oral, injection, transdermal patch, implant, cervical ring).\n    2. Barrier method (condom with spermicide or diaphragm with spermicide) every time during intercourse.\n    3. Intrauterine device.\n    4. Monogamous relationship with vasectomized partner (partner must have been vasectomized for at least 6 months prior to the subject's enrollment.\n16. Subjects of childbearing potential who are sexually active with men and refuse acceptable contraceptive method up to 28 days after the vaccination.\n17. Any positive or indeterminate pregnancy test.\n18. Planned vaccination (during the trial conduct) against any other vaccine preventable disease.\n19. Planned travel (during the trial) to any YFV endemic area.\n20. Screening serology consistent with prior history of dengue, zika, West Nile or Japanese encephalitis virus infection.\n\nIt may occur that a prospective subject meets all entry criteria except one that relates to short term clinical condition (e.g., fever, recent use of excluded medications). Under these circumstances, eligibility for delayed trial enrollment may be considered after inclusion\u002Fexclusion criteria have been rechecked, and if the subject is confirmed to be eligible.","20 Years","49 Years",{"count":125,"type":22},35,"INTERVENTIONAL",[128,129],"PHASE1","PHASE2","The goal of this clinical trial is to assess the immune response to the yellow fever vaccine 17D in adults with prior 17D vaccination. The main questions this study aims to answer are:\n\n* how does prior vaccination affect antibody responses to re-vaccination?\n* how does prior vaccination affect the immune cell response to re-vaccination?\n\nParticipants will:\n\n* have been previously vaccinated with 17D.\n* be re-vaccinated with 17D.\n* provide medical and travel histories.\n* provide a blood sample prior to vaccination\n* provide a blood sample approximately every other day for 14 days after vaccination.\n* provide a blood sample approximately 28 days after vaccination.\n* complete a daily diary of symptoms following vaccination for 14 days.\n* report any additional symptoms after 14 days.",[42,132],"Immunization; Infection",[134,135,136],"17D","vaccination","immunity","2025-07-28",{"date":139,"type":106},"2025-07-31",{"date":141,"type":106},"2023-08-01",{"date":143,"type":22},"2025-12-31",{"name":145,"class":113},"Oregon Health and Science University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":16,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":126,"phases":157,"briefSummary":159,"conditions":160,"keywords":161,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":114},"100578787","phase-3-non-interference-study-of-mr-and-yellow-fever-vaccines-among-bangladeshi-infants-aged-9-12-months-100578787","NCT06815835","Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","A Prospective, Randomized, Parallel, Three-arm, Open-label, Clinical Trial to Evaluate the Immunological Non-interference of Measles and Rubella Vaccine (Live) I.P. (Freeze Dried) of M\u002Fs. Zydus Lifesciences Ltd. With Yellow Fever Vaccine Administered to Bangladeshi Healthy Infants Aged 9-12 Months","Inclusion Criteria:\n\n* The participant must satisfy all the following criteria to be eligible for enrolment:\n* Healthy infant participants of either gender aged\\* 9 to 12 months at the time of enrollment\n* Participants should be in good health as determined by the medical history and physical examination based on the clinical judgment of the investigator\n* No previous history of vaccination against measles, rubella, or Yellow fever\n* Written informed consent from the participant's parent\u002Fguardian\n* Participant's parent\u002Fguardian literate enough to fill the diary card \\*Age calculated as per completed month\n\nExclusion Criteria:\n\n* Participants positive for serological markers against Dengue and\u002For Japanese Encephalitis infections\n* History of hypersensitivity reaction to any component of the study vaccines including egg and chicken proteins\n* History of hypersensitivity reaction to neomycin\n* History of laboratory-confirmed or suspected measles, rubella, or Yellow fever in the past\n* Participant exposed# to measles, rubella, or Yellow fever virus within the past 30 days\n* Fever of any origin or infectious disorder of 3 days or more within the past month\n* Febrile illness (axillary temperature ≥37.5°C) at the time of enrollment\n* History of any vaccination within the past month\n* Clinically significant systemic disorders such as cardiovascular, respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, haematological, immunological, or metabolic disorder\n* Confirmed or suspected immunosuppressive or immunodeficiency disorder; or participants on any immunosuppressive or immunostimulant therapy\n* Known case of thrombocytopenia or any coagulation disorder, or participants on anticoagulation therapy\n* Participants administered blood, blood-containing products, or immunoglobulins within the last 3 months or planned administration during the study\n* Participant participated in another clinical study in the past 3 months\n* Any other reason for which the investigator feels that the participant should not participate #Close contact (family member or neighbour) with laboratory-confirmed or clinical diagnosis of measles\u002Frubella\u002FYellow fever","9 Months","12 Months",{"count":156,"type":22},1530,[158],"PHASE3","This study will be conducted among 1530 healthy infants of 9 to 12 months of age residing in the Dakshinkhan and Uttarkhan area which is located in Dhaka North City Corporation (DNCC) to enroll the required number of participants. Only infants who have not previously received the MR and YF vaccines will be enrolled. The findings of this study are likely to have a significant impact on vaccine co-administration strategies for campaign and routine immunization programs. The participants will be assigned to one of the three groups by the central computer-generated randomization schedule. The numbers are defined for each arm (Table 1) based on the sample size calculation. A list of infants who did not receive MR and Yellow fever vaccine will be prepared before enrollment by trained study staff (TSS). The TSSs will visit households in the defined study area and ask if the parents\u002Fguardians of infants aged 9-12 months are willing to participate in the study. If they show a willingness to participate, the TSSs will check their vaccination cards (if available) and prepare the list of potentially eligible infants who have not received MR and Yellow fever vaccines based on their vaccination card status. The investigators will collect blood specimens (4-5 ml) at the time of screening (visit-1), to evaluate serological markers of dengue and Japanese Encephalitis infection and for baseline (pre-vaccination) immunological assessment. The investigators will vaccinate seronegative, eligible participants within 24 hours of blood collection. There will be additional three follow-up visits after enrollment and will collect around 3-4 ml blood from each participant during visit 4 (week 6), and visit 5 (week 26) for immunological assessment. Diary cards will be used to collect adverse events (AEs) following immunization (AEFI) data for vaccinated participants (up to 14 days for solicited and 6 weeks for unsolicited AEs). Medically attended adverse events (MAAEs) and data on serious adverse events (SAEs) will be reported during the study. All study updates including AEs and SAEs will be reported to the data safety and monitoring board (DSMB) and sponsor.",[48,50,42],[162,163,164,165,166],"Safety","Non-interference","Measles and Rubella","Co-administration","Immunogenicity","NOT_YET_RECRUITING","2025-02-06",{"date":170,"type":106},"2025-02-07",{"date":172,"type":22},"2025-04-01",{"date":174,"type":22},"2026-03-31",{"name":176,"class":113},"International Centre for Diarrhoeal Disease Research, Bangladesh",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":16,"sex":17,"minAge":184,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":126,"phases":187,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":198,"locationsCount":4},"100473890","immunity-to-yellow-fever-in-hiv-infected-patients-10-years-after-a-primary-anti-yellow-fever-vaccination-100473890","NCT05450770","Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination","The Yellow Fever Vaccine Immunity in HIV Infected Patients: Studies of Immunological Responses at 10 Years (ANRS 0146s NovaaTen)","Inclusion Criteria:\n\n* Subjects included in the ANRS EP 46 NOVAA trial:\n\n  * 40 HIV positive subjects from consultations for infectious diseases and travel medicine centers at Saint-Louis, Cochin-Pasteur and Bichat hospitals (on HAART for at least one year and not modified in the 3 months preceding the pre-inclusion visit, CD4 \\> 350\u002Fmm3 and a viral load \\\u003C50 copies \u002F mL for at least 6 months).\n  * 20 HIV negative subjects from the consultation of travelers from Saint-Louis, Bichat and Cochin-Pasteur hospitals.\n  * Subjects agreeing to be monitored according to the terms of the protocol.\n  * Subjects affiliated to a Social Security scheme or beneficiaries of such a scheme.\n  * Signature of informed consent.\n\nExclusion Criteria:\n\n* Non-volunteers for the 10-year follow-up\n* Subject under curatorship, guardianship or safeguard of justice.","18 Years",{"count":186,"type":22},60,[188],"NA","ANRS 0146s NovaaTen study aims to determine the vaccine responses in the participants of the ANRS EP46 Novaa trial 10 years after a primary anti-yellow fever vaccination",[191,42],"HIV Infections","2024-07-29",{"date":194,"type":106},"2024-07-30",{"date":196,"type":22},"2024-11-01",{"date":196,"type":22},{"name":199,"class":200},"ANRS, Emerging Infectious Diseases","OTHER_GOV"]